Asia Pacific Active Pharmaceutical Ingredients Market Forecast 2019-2027
- Report Description Table of Contents
- FAQs
KEY FINDINGS
There are various chemicals included in the drugs and the portion that works in treating the condition, i.e., the active part is known as Active Pharmaceutical Ingredients' or API in short. While each drug also consists of an excipient part, known as a carrier, it is the API that is considered while prescribing a drug.
The Asia Pacific active pharmaceutical ingredients market is escalating at a significant growth rate of 7.45% CAGR during the forecasting years of 2019-2027. The availability of cheap labor in this densely populated region coupled with the establishment of market players in the developing countries in APAC is expected to drive the market growth.
MARKET INSIGHTS
The economies of China, India, Japan, South Korea, Australia and the remaining countries collectively forming the Rest of Asia Pacific regional segment are the major revenue contributors to the APAC active pharmaceutical ingredients market. The healthcare expenditure in China is projected to reach a huge value soon because the nation shelters the largest population in the world, where there has been a significant rise in chronic conditions such as that of cancer, cardiovascular diseases, diabetes, and obesity, etc. These factors collectively create a huge scope for API market development.
Japan makes up another significantly large market in the Asia Pacific region for the API market. The high rise in geriatric population in the country coupled with higher expectation for an enhanced quality of life will be driving the market demand in the country.
COMPETITIVE INSIGHTS
The major market players operating in the APAC region, which are exhaustively profiled in terms of their adopted market strategies, business segments are Teva Pharmaceutical Industries, Ltd., Merck & Co., Inc., Abbvie, Inc., Cipla, Bristol-Myers Squibb, Dr. Reddy's Laboratories, Sun Pharmaceuticals Industries, Ltd., Mylan N.V., Bayer AG, Eli Lilly and Company, Novartis, Albemarle Corporation, Lonza Group AG, Aurobindo Pharma, and Boehringer Ingelheim GmbH.
There are various chemicals included in the drugs and the portion that works in treating the condition, i.e., the active part is known as Active Pharmaceutical Ingredients' or API in short. While each drug also consists of an excipient part, known as a carrier, it is the API that is considered while prescribing a drug.
The Asia Pacific active pharmaceutical ingredients market is escalating at a significant growth rate of 7.45% CAGR during the forecasting years of 2019-2027. The availability of cheap labor in this densely populated region coupled with the establishment of market players in the developing countries in APAC is expected to drive the market growth.
MARKET INSIGHTS
The economies of China, India, Japan, South Korea, Australia and the remaining countries collectively forming the Rest of Asia Pacific regional segment are the major revenue contributors to the APAC active pharmaceutical ingredients market. The healthcare expenditure in China is projected to reach a huge value soon because the nation shelters the largest population in the world, where there has been a significant rise in chronic conditions such as that of cancer, cardiovascular diseases, diabetes, and obesity, etc. These factors collectively create a huge scope for API market development.
Japan makes up another significantly large market in the Asia Pacific region for the API market. The high rise in geriatric population in the country coupled with higher expectation for an enhanced quality of life will be driving the market demand in the country.
COMPETITIVE INSIGHTS
The major market players operating in the APAC region, which are exhaustively profiled in terms of their adopted market strategies, business segments are Teva Pharmaceutical Industries, Ltd., Merck & Co., Inc., Abbvie, Inc., Cipla, Bristol-Myers Squibb, Dr. Reddy's Laboratories, Sun Pharmaceuticals Industries, Ltd., Mylan N.V., Bayer AG, Eli Lilly and Company, Novartis, Albemarle Corporation, Lonza Group AG, Aurobindo Pharma, and Boehringer Ingelheim GmbH.
Asia Pacific Active Pharmaceutical Ingredients Market Forecast 2019-2027
Published By :Inkwood Research
How to Purchase
Purchase reports from our site in few easy clicks. Please follow the description given below to complete your purchase process.
Step 1:
Select the report title of your interest, and Click on Buy Now button next to the Price option.
Step 2:
You will arrive at the Purchase page, where you will be requested to Signup (New User) or Login (Registered User). Please note that in-keeping with the security check on the website, you must submit your full details to avoid any inconvenience arising from incorrectly entered data or counterfeit information.
Step 3:
After SignUp/Login, you will arrive at our Payment Page on Paypal. You will see your Order Summary as well as an option to Choose a way to pay. Select a Payment option from Pay with a Paypal account OR Pay with a Debit or Credit Card. MarketReportOnline accepts Visa, MasterCard, American Express and Discover through Paypal. Fill up the required details in the option of your choice.
Step 4:
Once you follow the required process in Step 3 as mentioned above, you have successfully completed the purchase process.
Step 5:
Once you have successfully completed the purchase process, you will receive a confirmation email. The report will then be emailed to you directly by the publisher, as per our agreement with the publisher. For Orders that are placed after working hours, the delivery of the reports will be made on the next business day. For orders that are placed during weekends, the delivery of the reports will be made on the next 'working' business day. Please note, if you select purchase by invoice, you will receive your report only once the payment has been received. If you have any queries about how to order, please Contact Us.